TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Time To The Maximum Plasma Concentration (Tmax) Of Total GAA And rhGAA Protein In Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major morbidity and mortality
Endpoint domain: Mortality/survival
Primary endpoint: Time to at Least a 1 Point Improvement on the Patient's Global Assessment of Disease Severity (PatGA) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Auditory Event-related Potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Geometric mean titer (GMT) of anti-TBEV-antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Height SDS (standard deviation score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10m sprint score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 20m sprint score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Countermovement Jump (CMJ) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agility test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Yo-Yo Intermittent Recovery Test Level 1 (Yo-Yo IR1) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vz/F
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Proliferation Rate (Ki-67)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reperfusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fractional exhaled nitric oxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Spatio-temporal parameters of gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: salivary EGF concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV-Risk Behavior Outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in Weighted Mean 0-6 Hour FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Acute Success of Ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Correct placements of the ventricular catheter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Acute ventricular revisions
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum isometric muscular strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DSI less than/equal to 18.3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colonoscopy completion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Total Time of Active Ablation Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean Airway Pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: All types of complication
Endpoint domain: Adverse events/effects
Primary endpoint: Pre-school Language Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent change of ongoing pregnancy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Prolonged Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area under the aggregation curve in the ADPtest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Chronic insomnia
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Daytime functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Participants Achieving Serotype-Specific Pneumococcal IgG Antibody Level ≥0.35 Mcg/mL 1 Month After the Infant Series
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Achieving Serotype-Specific Pneumococcal IgG Antibody Level ≥0.35 Mcg/mL 1 Month After the Toddler Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Achieving Serotype-Specific Pneumococcal IgG Antibody Level ≥0.35 Mcg/mL 1 Month After the Relevant Catch-Up Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety of autologous cardiac-derived stem cells
Endpoint domain: Adverse events/effects
Primary endpoint: composite virologic and biochemical response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change in Oestrogen Receptor (ER) H-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage Change in Progesterone Receptor (PgR) H-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage Change in Ki67 Labelling Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: complications associated with delivery and/or use of the Ardian Catheter
Endpoint domain: Adverse events/effects
Primary endpoint: adverse renal events
Endpoint domain: Adverse events/effects
Primary endpoint: electrolyte disturbances
Endpoint domain: Adverse events/effects
Primary endpoint: hemodynamic events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of postprandial self monitored blood glucose (SMBG) values within the target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cerebral ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 6 Minute Walk Distance (6-MWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum TTR Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inter-rater agreement on assignment of nevi to RCM patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion achieving clinical response at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delivery or fetal loss of either twin prior to 35 weeks gestation
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of subjects achieving clinical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Oxidized Phosphatidylcholines in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Technical success of the direct peroral cholangioscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of participants retained continuously in quality HIV care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants who are virally suppressed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain after mechanical instrumentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative apnea-hypopnea index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants With Local and Systemic Immediate Reactogenicity Complaints
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of severe stunting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of serious and non-serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes of perfused vessel density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Adverse Event Score
Endpoint domain: Adverse events/effects
Primary endpoint: Area of allodynia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of 68Ga PSMA-11 PET-positive Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Overall Detected Thyroid Cancer Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean Standardized Uptake Value Maximum of Gallium-68 PSMA (SUVmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Failure of extubation
Endpoint domain: Adverse events/effects
Primary endpoint: Change in XeQoLS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to First Protocol-Defined Relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve From Time Zero to 6 Hours Post-dose (AUC[0-6])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Concentration (Cmax) for Total Epinephrine From Time Zero to 6 Hours Post-dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life (t1/2) for Total Epinephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease Activity Score Based on 28-joints Count (DAS28)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IOP fluctuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Soft Tissue Healing Post Extraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Treated Participants With Successful Neutrophil and Platelet Engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Transplant Related Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Overall Survival (OS) Events
Endpoint domain: Mortality/survival
Primary endpoint: Effectiveness of chemotherapy treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Difference in math achievement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Average volume of physical activity per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-Day unscheduled hospital readmission or emergency visit rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Effectiveness of cryotherapy modality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients maintained on monotherapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Safety of superselective intra-arterial cerebral infusion of Temozolomide
Endpoint domain: Adverse events/effects
Primary endpoint: Trail making test performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Single letter verbal fluency performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rey Auditory Verbal Learning Test performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Letter-Number Sequencing performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: P2Y12 Reaction Units (PRU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Time Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in mean PAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: decrease in pulmonary vascular resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: improvement of functional capacity by the 6MWT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduced bone strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Plasma cortisol change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Vaginal group B streptococcus colonies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevalence of any-grade of esophageal dysplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Follicle growth and maturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: muscle torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropsychologic testing scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Hearing Handicap Inventory for the Elderly (HHIE)-S
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of Intraoperative Desaturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Skin Diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Fasted glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in 2hour glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of healing of the ICD episode defined as absence of diarrhea within 48 hours after the end of the episode treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of cardiological safety events
Endpoint domain: Adverse events/effects
Primary endpoint: Change of amplitude of N200
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pathologic Complete Response (pCR) Rate
Endpoint domain: Mortality/survival
Primary endpoint: Incidence rate of acute myocardial infarction and cardiovascular disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Short-Form McGill Pain Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Present Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantity of narcotic consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Hypokinesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI characteristics of lung changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Electrical potential of ionic channel in the synovial fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: efficacy of influenza A/H1N1 adjuvanted-vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: safety of influenza A/H1N1 adjuvanted-vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic Quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of diastolic dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average maximum plasmatic concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the pharmacokinetic curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Canadian Occupational Performance Measure (COPM)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fahn Dystonia Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events Grade 2 or higher
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage With Erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage With Edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage With Scaling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: frequency of postoperative complication occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Healthcare resource use
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in CMAI Composite Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in heart rate at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in heart rate during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in flicker fusion frequency test (FFF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of patients with undetectable viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in the number of CD4 + T cells at 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to loss of virological efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reactive Hyperemic Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Feasibility of co-registration of sMRI-based treatment volumes
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in total daily insulin requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Response to treatment with Y90 microspheres
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Methacholine challenge test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline on a Composite Measure of Attention, Working Memory, and Executive Functions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Clinical pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Quantification of endomysial fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Quantification of muscle inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cumulative Dose of Capecitabine Until the Development of Grade 2 or Higher Hand-foot Syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of adverse events (AE/SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of skin involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Rate of repigmentation lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Overall Response (OR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sexual Probability Discounting (SexPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standard Delay Discounting (DD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Barrat Impulsiveness Scale (BIS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Risk Assessment Battery (RAB)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of DLT
Endpoint domain: Adverse events/effects
Primary endpoint: Number of treatment related AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Stratified by Treatment Patterns
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Development of contrast induced nephropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Postpartum hemorrhage incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change From Baseline in Asthma Control Questionnaire (ACQ) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ADHD Rating Scale - IV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of antibodies (Abs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Drinking-Related Negative Consequences
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Radiographic changes in the low back
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: False negative rate acceptance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in sleep parameters via polysomnography
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Changes in symptom severity as measured by Insomnia Severity Index
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Changes in symptom severity as measured by Pittsburgh Sleep Quality Index
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: variceal rebleeding rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes